Travere Therapeutics, Inc. (TVTX) P/E Ratio History
Historical price-to-earnings valuation from 2015 to 2016
Loading P/E history...
TVTX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Travere Therapeutics, Inc. (TVTX) trades at a price-to-earnings ratio of -76.2x, with a stock price of $42.66 and trailing twelve-month earnings per share of $-0.23.
The current P/E is 687% below its 5-year average of 13.0x. Over the past five years, TVTX's P/E has ranged from a low of 8.4x to a high of 15.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, TVTX trades at a 441% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, TVTX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TVTX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TVTX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9 | - | +68% | |
| $5B | 8.3Lowest | - | +264% | |
| $9B | 43.4 | - | +128% | |
| $39B | 127.0 | - | +207% | |
| $108B | 27.7 | 3.35Best | +837%Best | |
| $10B | 30.1 | - | -19% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TVTX Historical P/E Data (2015–2016)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2016 Q2 | $17.81 | $1.26 | 14.1x | +8% | |
| FY2016 Q1 | $13.66 | $0.91 | 15.1x | +16% | |
| FY2015 Q4 | $19.29 | $2.31 | 8.4x | -36% | |
| FY2015 Q3 | Wed Sep 30 2015 00:00:00 GM | $20.26 | $1.41 | 14.4x | +11% |
Average P/E for displayed period: 13.0x
See TVTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TVTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TVTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTVTX — Frequently Asked Questions
Quick answers to the most common questions about buying TVTX stock.
Is TVTX stock overvalued or undervalued?
TVTX trades at -76.2x P/E, below its 5-year average of 13.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does TVTX's valuation compare to peers?
Travere Therapeutics, Inc. P/E of -76.2x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is TVTX's PEG ratio?
TVTX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2015-2016.